Want to stay on top of the science and politics driving biotech today? Sign up to get our biotech newsletter in your inbox.
Morning! Today, we see that the FDA is extending its review period for multiple myeloma drug Blenrep. We also see more layoffs at a gene-editing company, and hear Alnylam’s CEO advocate for a new policy when it comes to Medicare price negotiations.
The need-to-know this morning
Roche reported second-quarter earnings.
Rocket Pharmaceuticals announced a restructuring that will include layoffs affecting 30% of its employees. The company is reducing its cash burn by 25% to focus on gene therapies for cardiovascular conditions. It will no longer pursue the approval of a gene therapy for Fanconi anemia.
FDA delays GSK’s Blenrep decision again
From my colleague Andrew Joseph: The wait for a Food and Drug Administration approval decision on GSK’s blood cancer drug Blenrep is going to take a little longer.
STAT+ Exclusive Story
Already have an account? Log in
This article is exclusive to STAT+ subscribers
Unlock this article — plus in-depth analysis, newsletters, premium events, and news alerts.
Already have an account? Log in
Individual plans
Group plans
To read the rest of this story subscribe to STAT+.